The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- CAGR of 5.3% | Hemophilia Treatment Drugs Market expected to reach USD 25660.57 Million by 2025on January 22, 2021 at 9:12 am
Jan (Heraldkeepers) -- Hemophilia Treatment Drugs Market is valued around USD 18091.26 Million in 2018 and expected to reach USD 25660.57 Million ...
- Hemophilia A Treatment Market 2021, Top Leading Countries,Trends, Forces Analysis, Revenue, Challenges and Global Forecast 2026on January 21, 2021 at 9:12 pm
Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of ...
- Spark co-founder Kathy High joins a longtime collaborator at AskBio, helping steer Bayer's gene therapy pushon January 12, 2021 at 11:02 am
Kathy High has re-emerged in the gene therapy space just as unexpectedly as she left Spark Therapeutics close to a year ago. Her newest title will be president, therapeutics at AskBio, the biotech “ra ...
- BioMarin tries to get hemophilia gene therapy back on track with positive dataon January 11, 2021 at 7:10 am
Full one-year results from a Phase 3 study show the therapy, known as Roctavian, sharply reduced bleeds and use of blood-clotting treatments.
- 5 questions facing gene therapy in 2021on January 8, 2021 at 9:34 am
Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth. Dealmaking, however, appears to be continuing apace.
- Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational ...on January 1, 2021 at 4:00 pm
The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license ...
- CSL pact intact as Uniqure works to FIX hemophilia B gene therapy stallon December 28, 2020 at 4:00 pm
Amsterdam-based Uniqure NV’s regulatory hitch with its highly regarded hemophilia B program had analysts questioning during a conference call what the development might mean for the company’s deal ...
- Highlights From the XXV International Congress of the World Federation of Hemophiliaon December 26, 2020 at 4:00 pm
The XXV International Congress of the World Federation of Hemophilia (WFH) recently held in Seville, Spain, offered the opportunity for healthcare providers and members of the community from all ...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QUREon December 26, 2020 at 2:50 pm
On December 21, 2020, uniQure disclosed that its hemophilia B gene therapy program, including the Company's pivotal, Phase III HOPE-B study, had been placed on clinical hold by the U.S. Food and Drug ...
via Bing News